Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based Study
Theresa H.M. Keegan(UC Davis Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Sally L. Glaser, Fiona E. Craig(The University of Texas at San Antonio Health Science Center), Margaret L. Gulley(University of North Carolina at Chapel Hill), Risa B. Mann(Boston University), Christina A. Clarke(Menlo School), Ronald F. Dorfman(Stanford Medicine), Joseph A. DiGiuseppe(Hartford Hospital)
Cited by 168
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
|Journal of Clinical Oncology|2001|610
Hodgkin lymphoma: A review and update on recent progress
|CA A Cancer Journal for Clinicians|2017|479
Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide
|New England Journal of Medicine|1986|441